{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:31:20Z","timestamp":1757313080230,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:00:00Z","timestamp":1538179200000},"content-version":"vor","delay-in-days":271,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/j.curtheres.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:27:06Z","timestamp":1539044826000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study"],"prefix":"10.1016","volume":"89","author":[{"given":"Diego","family":"Bellido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-3946","authenticated-orcid":false,"given":"Pablo","family":"Abell\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Ruiz Palomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"\u00c1lvarez Sintes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreu","family":"Nubiolae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-043X","authenticated-orcid":false,"given":"Virginia","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gracia","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2018.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1185\/03007995.2013.852078","article-title":"Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review","volume":"30","author":"Goldenberg","year":"2014","journal-title":"Current medical research and opinion"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0003","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/dom.12286","article-title":"The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial","volume":"16","author":"Lane","year":"2014","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0004","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0006","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.1507","article-title":"GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents","volume":"34","author":"Trujillo","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2017.1251579","article-title":"Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus","author":"Hanefeld","year":"2017","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0008","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes care"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0009","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes care"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0011","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc16-0014","article-title":"Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes care"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0012","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdiacomp.2013.10.003","article-title":"Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials","volume":"28","author":"Raccah","year":"2014","journal-title":"Journal of diabetes and its complications"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0013","article-title":"Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering","author":"Fleischmann","year":"2016","journal-title":"Diabetes & metabolic syndrome"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0014","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.aprim.2016.06.009","article-title":"Lixisenatida en pacientes con diabetes tipo 2 y obesidad: m\u00e1s all\u00e1 del control gluc\u00e9mico","volume":"49","author":"Roca-Rodr\u00edguez","year":"2017","journal-title":"Aten Primaria"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0015","doi-asserted-by":"crossref","first-page":"18C","DOI":"10.1016\/S0828-282X(10)71077-1","article-title":"Prevention of cardiovascular disease: obesity, diabetes and the metabolic syndrome","volume":"26","author":"Padwal","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/DMSO.S130834","article-title":"Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research","volume":"10","author":"Levin","year":"2017","journal-title":"Diabetes, metabolic syndrome and obesity: targets and therapy"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0017","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0018","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0019","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2337\/dc16-1495","article-title":"Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial","volume":"39","author":"Aroda","year":"2016","journal-title":"Diabetes care"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1463-1326.2012.01606.x","article-title":"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis","volume":"14","author":"Liu","year":"2012","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0021","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1080\/14656566.2016.1206079","article-title":"Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus","volume":"17","author":"Forst","year":"2016","journal-title":"Expert opinion on pharmacotherapy"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2042018814556099","article-title":"Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making","volume":"5","author":"Scholz","year":"2014","journal-title":"Therapeutic advances in endocrinology and metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0023","doi-asserted-by":"crossref","first-page":"6S21","DOI":"10.1016\/S1262-3636(16)30005-2","article-title":"Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?","volume":"41","author":"Darmon","year":"2015","journal-title":"Diabetes & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/dom.12136","article-title":"Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy","volume":"16","author":"Hirsch","year":"2014","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"6S16","DOI":"10.1016\/S1262-3636(16)30004-0","article-title":"GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials","volume":"41","author":"Porcellati","year":"2015","journal-title":"Diabetes & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/dom.12810","article-title":"Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme","volume":"19","author":"Broglio","year":"2017","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1016\/j.curtheres.2018.09.001_bib0027","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13098-015-0104-6","article-title":"Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials","volume":"7","author":"Eto","year":"2015","journal-title":"Diabetology & metabolic syndrome"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X18300298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X18300298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:06:12Z","timestamp":1556755572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X18300298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":27,"alternative-id":["S0011393X18300298"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2018.09.001","relation":{},"ISSN":["0011-393X"],"issn-type":[{"type":"print","value":"0011-393X"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}